Related Experiment Videos
Increased interleukin-10 serum levels in patients with solid tumours
C Fortis1, M Foppoli, L Gianotti
1Adoptive Immunotherapy Laboratory, IRCCS H San Raffaele, Milan, Italy.
Cancer Letters
|June 24, 1996
Summary
Elevated serum levels of interleukin-10 (IL-10) were found in 40% of stage IV solid tumor patients. Higher IL-10 in melanoma and certain adenocarcinomas suggests immune evasion in cancer.
Area of Science:
- Oncology
- Immunology
Background:
- Interleukin-10 (IL-10) is a cytokine that suppresses immune and inflammatory responses.
- Elevated IL-10 levels have been observed in various cancers, potentially aiding tumor immune evasion.
Purpose of the Study:
- To investigate serum levels of IL-10 in patients with stage IV solid tumors.
- To compare IL-10 levels across different cancer types and with healthy controls.
Main Methods:
- Serum samples were collected from 99 patients with stage IV solid tumors and healthy subjects.
- Interleukin-10 levels were quantified using immunoassays.
- Statistical analysis was performed to compare IL-10 levels between groups.
Main Results:
- 40.4% of cancer patients exhibited elevated serum IL-10 levels.
- Significantly higher IL-10 levels were observed in patients with malignant melanoma, pancreatic, and gastric adenocarcinoma compared to healthy controls.
- Patients with colon and renal carcinoma showed IL-10 levels similar to controls.
Conclusions:
- Increased circulating IL-10 in certain advanced solid tumors may indicate a mechanism for immune escape.
- These findings highlight IL-10's potential role in cancer progression and immune surveillance.
- Further research into IL-10's implications for cancer monitoring and therapy is warranted.